{"id":72173,"date":"2026-08-10T13:29:16","date_gmt":"2026-08-10T05:29:16","guid":{"rendered":"https:\/\/flcube.com\/?p=72173"},"modified":"2026-08-10T13:29:16","modified_gmt":"2026-08-10T05:29:16","slug":"kelun-biotech-signs-commercialization-deal-with-new-frontier-health-for-sacituzumab-tirumotecan-in-hong-kong-and-macao","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72173","title":{"rendered":"Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Kelun-Biotech<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/6990:HKG\">HKG: 6990<\/a>) announced a <strong>strategic commercialization agreement<\/strong> with <strong>New Frontier Health Technology<\/strong>, a subsidiary of <strong>New Frontier Group<\/strong>, for <strong>sacituzumab tirumotecan<\/strong> (sac\u2011TMT, also known as <strong>SKB264\/MK\u20112870<\/strong>; trade name: <strong>Sac\u2011TMT\/Jia Tai Lai<\/strong>) across <strong>Hong Kong SAR<\/strong> and <strong>Macao SAR<\/strong>, China. The agreement extends the commercial footprint of the company&#8217;s flagship <strong>TROP2 antibody\u2011drug conjugate (ADC)<\/strong> beyond Mainland China.<\/p>\n\n\n\n<h2 id=\"h-deal-overview\" class=\"wp-block-heading\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Kelun-Biotech (HKG: 6990)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>New Frontier Health Technology (subsidiary of New Frontier Group)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Sacituzumab tirumotecan (sac\u2011TMT \/ SKB264 \/ MK\u20112870; trade name Sac\u2011TMT \/ Jia Tai Lai)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Antibody\u2011drug conjugate (ADC)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Human trophoblast cell surface antigen 2 (TROP2)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Hong Kong SAR and Macao SAR, China<\/td><\/tr><tr><td><strong>Deal Type<\/strong><\/td><td>Strategic commercialization agreement<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>10 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile\" class=\"wp-block-heading\">Product Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Sacituzumab tirumotecan, an <strong>ADC independently developed by Kelun\u2011Biotech<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>TROP2<\/strong> (human trophoblast cell surface antigen 2)<\/li>\n\n\n\n<li><strong>Approval Status:<\/strong> Currently holds <strong>4 approved indications in Mainland China<\/strong><\/li>\n\n\n\n<li><strong>Asset Codes:<\/strong> Known as <strong>SKB264<\/strong> (Kelun\u2011Biotech) and <strong>MK\u20112870<\/strong> (MSD), reflecting the asset&#8217;s dual development identity under the global partnership<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-global-partnership-structure\" class=\"wp-block-heading\">Global Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Rights Holder<\/th><\/tr><\/thead><tbody><tr><td><strong>Outside Greater China<\/strong><\/td><td><strong>MSD<\/strong> (NYSE: MRK) \u2014 exclusive rights to develop, use, manufacture, and commercialize (licensed May 2022)<\/td><\/tr><tr><td><strong>Greater China (Mainland China, Hong Kong, Macao, Taiwan)<\/strong><\/td><td><strong>Kelun\u2011Biotech<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">In <strong>May 2022<\/strong>, Kelun\u2011Biotech granted <strong>MSD<\/strong> (NYSE: MRK) exclusive rights to develop, use, manufacture, and commercialize sacituzumab tirumotecan in all regions <strong>outside of Greater China<\/strong>. The new agreement with New Frontier Health Technology covers territories <strong>within<\/strong> Greater China where Kelun\u2011Biotech retains full rights, complementing \u2014 rather than overlapping with \u2014 the MSD alliance.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Expansion:<\/strong> The deal marks sacituzumab tirumotecan&#8217;s first dedicated commercialization arrangement for Hong Kong and Macao, extending a product already generating approvals in four Mainland China indications.<\/li>\n\n\n\n<li><strong>ADC Momentum:<\/strong> TROP2\u2011directed ADCs remain one of the most active segments of oncology dealmaking, and Kelun\u2011Biotech&#8217;s asset \u2014 with its MSD\u2011backed global program \u2014 is among the most closely watched in the class.<\/li>\n\n\n\n<li><strong>Channel Strategy:<\/strong> Partnering with New Frontier Health Technology, a healthcare services and distribution player, suggests a commercial model leveraging established regional channels rather than building an in\u2011field force in the two SARs.<\/li>\n\n\n\n<li><strong>Rights Architecture:<\/strong> The structure keeps Greater China economics under Kelun\u2011Biotech control while MSD monetizes ex\u2011Greater China markets \u2014 a clean division that maximizes value capture on both sides.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the commercialization of sacituzumab tirumotecan in Hong Kong SAR and Macao SAR. Actual results may differ due to risks including regulatory developments, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary&#8230;<\/p>\n","protected":false},"author":1,"featured_media":72175,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[971,1832,176],"class_list":["post-72173","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-6990","tag-kelun-biotech-biopharmaceutical","tag-msd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary of New Frontier Group, for sacituzumab tirumotecan (sac\u2011TMT, also known as SKB264\/MK\u20112870; trade name: Sac\u2011TMT\/Jia Tai Lai) across Hong Kong SAR and Macao SAR, China. The agreement extends the commercial footprint of the company&#039;s flagship TROP2 antibody\u2011drug conjugate (ADC) beyond Mainland China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72173\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao\" \/>\n<meta property=\"og:description\" content=\"Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary of New Frontier Group, for sacituzumab tirumotecan (sac\u2011TMT, also known as SKB264\/MK\u20112870; trade name: Sac\u2011TMT\/Jia Tai Lai) across Hong Kong SAR and Macao SAR, China. The agreement extends the commercial footprint of the company&#039;s flagship TROP2 antibody\u2011drug conjugate (ADC) beyond Mainland China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72173\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T05:29:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1004.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72173#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72173\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao\",\"datePublished\":\"2026-08-10T05:29:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72173\"},\"wordCount\":441,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72173#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1004.webp\",\"keywords\":[\"HKG: 6990\",\"Kelun-Biotech Biopharmaceutical\",\"MSD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72173#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72173\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72173\",\"name\":\"Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72173#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72173#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1004.webp\",\"datePublished\":\"2026-08-10T05:29:16+00:00\",\"description\":\"Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary of New Frontier Group, for sacituzumab tirumotecan (sac\u2011TMT, also known as SKB264\\\/MK\u20112870; trade name: Sac\u2011TMT\\\/Jia Tai Lai) across Hong Kong SAR and Macao SAR, China. The agreement extends the commercial footprint of the company's flagship TROP2 antibody\u2011drug conjugate (ADC) beyond Mainland China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72173#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72173\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72173#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1004.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1004.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kelun\u2011Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72173#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao - Insight, China&#039;s Pharmaceutical Industry","description":"Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary of New Frontier Group, for sacituzumab tirumotecan (sac\u2011TMT, also known as SKB264\/MK\u20112870; trade name: Sac\u2011TMT\/Jia Tai Lai) across Hong Kong SAR and Macao SAR, China. The agreement extends the commercial footprint of the company's flagship TROP2 antibody\u2011drug conjugate (ADC) beyond Mainland China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72173","og_locale":"en_US","og_type":"article","og_title":"Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao","og_description":"Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary of New Frontier Group, for sacituzumab tirumotecan (sac\u2011TMT, also known as SKB264\/MK\u20112870; trade name: Sac\u2011TMT\/Jia Tai Lai) across Hong Kong SAR and Macao SAR, China. The agreement extends the commercial footprint of the company's flagship TROP2 antibody\u2011drug conjugate (ADC) beyond Mainland China.","og_url":"https:\/\/flcube.com\/?p=72173","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-10T05:29:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1004.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72173#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72173"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao","datePublished":"2026-08-10T05:29:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72173"},"wordCount":441,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=72173#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1004.webp","keywords":["HKG: 6990","Kelun-Biotech Biopharmaceutical","MSD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72173#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72173","url":"https:\/\/flcube.com\/?p=72173","name":"Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=72173#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=72173#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1004.webp","datePublished":"2026-08-10T05:29:16+00:00","description":"Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary of New Frontier Group, for sacituzumab tirumotecan (sac\u2011TMT, also known as SKB264\/MK\u20112870; trade name: Sac\u2011TMT\/Jia Tai Lai) across Hong Kong SAR and Macao SAR, China. The agreement extends the commercial footprint of the company's flagship TROP2 antibody\u2011drug conjugate (ADC) beyond Mainland China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72173#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72173"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=72173#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1004.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1004.webp","width":1080,"height":608,"caption":"Kelun\u2011Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72173#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1004.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72173"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72173\/revisions"}],"predecessor-version":[{"id":72176,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72173\/revisions\/72176"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/72175"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}